B-intervention	0	12	Preoperative
I-intervention	13	19	breast
I-intervention	20	23	MRI
O	24	27	for
O	28	33	early
O	33	34	-
O	34	39	stage
O	40	46	breast
O	47	53	cancer
O	53	54	:
O	55	61	effect
O	62	64	on
O	65	73	surgical
O	74	77	and
O	78	82	long
O	82	83	-
O	83	87	term
O	88	96	outcomes
O	96	97	.

O	98	101	The
O	102	109	purpose
O	110	112	of
O	113	117	this
O	118	123	study
O	124	127	was
O	128	130	to
O	131	139	evaluate
O	140	143	the
O	144	150	effect
O	151	153	of
O	154	157	the
O	158	161	use
O	162	164	of
O	165	177	preoperative
O	178	184	breast
O	185	188	MRI
O	189	191	on
O	192	200	surgical
O	201	204	and
O	205	209	long
O	209	210	-
O	210	214	term
O	215	223	outcomes
O	224	229	among
B-eligibility	230	235	women
I-eligibility	236	240	with
I-eligibility	241	246	early
I-eligibility	246	247	-
I-eligibility	247	252	stage
I-eligibility	253	259	breast
I-eligibility	260	266	cancer
I-eligibility	267	277	undergoing
I-eligibility	278	284	breast
I-eligibility	285	297	conservation
I-eligibility	298	305	therapy
O	305	306	.

O	307	308	A
O	309	322	retrospective
O	323	329	review
O	330	337	yielded
O	338	341	the
O	342	347	cases
O	348	350	of
B-intervention-participants	351	354	174
O	355	360	women
O	361	365	with
O	366	371	stage
O	372	373	0
O	373	374	,
O	375	376	I
O	376	377	,
O	378	380	or
O	381	383	II
O	384	390	breast
O	391	397	cancer
O	398	401	who
O	402	411	underwent
O	412	424	preoperative
O	425	428	MRI
O	429	436	between
O	437	441	2000
O	442	445	and
O	446	450	2004
O	450	451	.

O	452	453	A
B-control	454	461	control
I-control	462	467	group
O	468	470	of
B-intervention-participants	471	474	174
O	475	483	patients
O	484	487	who
O	488	491	did
O	492	495	not
O	496	503	undergo
O	504	516	preoperative
O	517	520	MRI
O	521	527	before
O	528	534	breast
O	535	547	conservation
O	548	555	therapy
O	556	559	was
O	560	567	matched
O	568	570	by
O	571	574	age
O	574	575	,
O	576	591	histopathologic
O	592	599	finding
O	599	600	,
O	601	606	stage
O	606	607	,
O	608	611	and
O	612	619	surgeon
O	619	620	.

O	621	629	Features
O	630	638	compared
O	639	647	included
O	648	654	breast
O	655	662	density
O	662	663	,
O	664	672	presence
O	673	675	of
O	676	692	mammographically
O	693	699	occult
O	700	707	disease
O	707	708	,
O	709	715	margin
O	716	722	status
O	722	723	,
O	724	729	lymph
O	730	734	node
O	735	746	involvement
O	746	747	,
O	748	762	lymphovascular
O	763	771	invasion
O	771	772	,
O	773	782	extensive
O	783	794	intraductal
O	795	804	component
O	804	805	,
O	806	813	hormone
O	814	822	receptor
O	823	829	status
O	829	830	,
O	831	834	and
O	835	838	use
O	839	841	of
O	842	850	adjuvant
O	851	858	therapy
O	858	859	.

O	860	868	Outcomes
O	868	869	,
O	870	879	including
O	880	885	rates
O	886	888	of
O	889	899	reexcision
O	899	900	,
O	901	912	ipsilateral
O	913	923	recurrence
O	923	924	,
O	925	928	and
O	929	936	disease
O	936	937	-
O	937	941	free
O	942	950	survival
O	950	951	,
O	952	956	were
O	957	965	compared
O	966	968	by
O	969	975	Kaplan
O	975	976	-
O	976	981	Meier
O	982	989	methods
O	990	993	and
O	994	997	the
O	998	1001	log
O	1001	1002	-
O	1002	1006	rank
O	1007	1011	test
O	1011	1012	.

O	1013	1021	Patients
O	1022	1030	referred
O	1031	1034	for
O	1035	1047	preoperative
O	1048	1054	breast
O	1055	1058	MRI
O	1059	1063	were
O	1064	1068	more
B-outcome	1069	1075	likely
I-outcome	1076	1078	to
I-outcome	1079	1083	have
I-outcome	1084	1093	extremely
I-outcome	1094	1099	dense
I-outcome	1100	1107	breasts
O	1108	1109	(
B-iv-bin-percent	1109	1111	28
I-iv-bin-percent	1111	1112	%
O	1113	1115	vs
B-cv-bin-percent	1116	1117	6
I-cv-bin-percent	1117	1118	%
O	1118	1119	,
O	1120	1121	p
O	1122	1123	<
O	1124	1125	0
O	1125	1126	.
O	1126	1130	0001
O	1130	1131	)
O	1132	1135	and
B-outcome	1136	1152	mammographically
I-outcome	1153	1159	occult
I-outcome	1160	1166	cancer
O	1167	1168	(
B-iv-bin-percent	1168	1170	24
I-iv-bin-percent	1170	1171	%
O	1172	1174	vs
B-cv-bin-percent	1175	1176	9
I-cv-bin-percent	1176	1177	%
O	1177	1178	,
O	1179	1180	p
O	1181	1182	=
O	1183	1184	0
O	1184	1185	.
O	1185	1189	0003
O	1189	1190	)
O	1190	1191	.

O	1192	1195	The
O	1196	1199	two
O	1200	1206	groups
O	1207	1210	had
O	1211	1220	identical
O	1221	1226	rates
O	1227	1229	of
O	1230	1235	final
O	1236	1244	negative
O	1245	1252	margins
O	1252	1253	,
O	1254	1259	lymph
O	1260	1264	node
O	1265	1276	involvement
O	1276	1277	,
O	1278	1292	lymphovascular
O	1293	1301	invasion
O	1301	1302	,
O	1303	1312	extensive
O	1313	1324	intraductal
O	1325	1334	component
O	1335	1341	status
O	1341	1342	,
O	1343	1351	positive
O	1352	1359	hormone
O	1360	1368	receptor
O	1369	1376	results
O	1376	1377	,
O	1378	1381	and
O	1382	1390	systemic
O	1391	1399	adjuvant
O	1400	1407	therapy
O	1407	1408	.

O	1409	1414	Fewer
O	1415	1423	patients
O	1424	1426	in
O	1427	1430	the
O	1431	1443	preoperative
O	1444	1447	MRI
O	1448	1453	group
B-outcome	1454	1460	needed
I-outcome	1461	1471	reexcision
O	1472	1473	(
B-iv-bin-percent	1473	1475	29
I-iv-bin-percent	1475	1476	%
O	1477	1479	vs
B-cv-bin-percent	1480	1482	45
I-cv-bin-percent	1482	1483	%
O	1483	1484	,
O	1485	1486	p
O	1487	1488	=
O	1489	1490	0
O	1490	1491	.
O	1491	1493	02
O	1493	1494	)
O	1494	1495	.

O	1496	1499	The
O	1500	1506	median
O	1507	1513	follow
O	1513	1514	-
O	1514	1516	up
O	1517	1523	period
O	1524	1529	after
O	1530	1539	treatment
O	1540	1543	was
O	1544	1545	8
O	1546	1551	years
O	1551	1552	.

O	1553	1558	There
O	1559	1562	was
O	1563	1565	no
O	1566	1577	significant
O	1578	1588	difference
O	1589	1591	in
B-outcome	1592	1604	locoregional
I-outcome	1605	1615	recurrence
O	1616	1617	(
O	1617	1618	p
O	1619	1620	=
O	1621	1622	0
O	1622	1623	.
O	1623	1625	33
O	1625	1626	)
O	1627	1629	or
B-outcome	1630	1637	disease
I-outcome	1637	1638	-
I-outcome	1638	1642	free
I-outcome	1643	1651	survival
O	1652	1653	(
O	1653	1654	p
O	1655	1656	=
O	1657	1658	0
O	1658	1659	.
O	1659	1661	73
O	1661	1662	)
O	1663	1668	rates
O	1669	1676	between
O	1677	1680	the
O	1681	1684	two
O	1685	1691	groups
O	1691	1692	.

B-outcome	1693	1703	Reexcision
I-outcome	1704	1709	rates
O	1710	1715	among
O	1716	1724	patients
O	1725	1729	with
O	1730	1735	early
O	1736	1742	breast
O	1743	1749	cancer
O	1750	1760	undergoing
O	1761	1773	conservation
O	1774	1781	therapy
O	1782	1786	were
O	1787	1792	lower
O	1793	1798	among
O	1799	1804	women
O	1805	1808	who
O	1809	1818	underwent
O	1819	1831	preoperative
O	1832	1838	breast
O	1839	1842	MRI
O	1842	1843	.

O	1844	1849	There
O	1850	1853	was
O	1854	1856	no
O	1857	1870	statistically
O	1871	1882	significant
O	1883	1889	effect
O	1890	1892	of
O	1893	1896	the
O	1897	1900	use
O	1901	1903	of
O	1904	1916	preoperative
O	1917	1920	MRI
O	1921	1923	on
O	1924	1929	rates
O	1930	1932	of
O	1933	1945	locoregional
O	1946	1956	recurrence
O	1957	1959	or
O	1960	1967	disease
O	1967	1968	-
O	1968	1972	free
O	1973	1981	survival
O	1981	1982	.
